Deepening Roots in China | Aligning with Healthy China Development, International Pharmaceutical Giants Double Down on China

GateUser-bd883c58 · 2026-03-23T19:20:40+00:00

Ask AI · How Does the 15th Five-Year Plan Policy Catalyze a Wave of Multinational Pharmaceutical Investment in China?Following the Two Sessions, pharmaceutical giants from around the world have visited in succession, calling on the Ministry of Commerce and other government departments to seize new opportunities in China as the 15th Five-Year Plan kicks off. China's measures are concrete and tangible, with foreign investment visible on the ground: U.S. pharma giant Eli Lilly announced a $3 billion investment in China; French Sanofi announced the official launch of its Innovation and Operations Center in Chengdu, China; British AstraZeneca established a commercialized cell therapy production supply base and innovation center in Shanghai ... Betting big on China, multinational pharmaceutical companies are moving at breakneck speed.

GateUser-bd883c58

2026-03-23 19:20:40

How do the AI and the 14th Five-Year Plan stimulate the surge of multinational pharmaceutical companies investing in China?

After the Two Sessions, many global pharmaceutical leaders have visited the Ministry of Commerce and other government departments, seizing the new opportunities in China at the start of the 14th Five-Year Plan. China’s measures are tangible, and foreign investment is visibly taking root: Eli Lilly from the US announced a $3 billion investment in China; Sanofi from France announced the official launch of its Innovation and Operations Center in Chengdu; AstraZeneca from the UK is establishing a cell therapy commercialization and production base and an innovation center in Shanghai… Major investments in China are ongoing, with multinational pharmaceutical companies moving swiftly.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes